References
1. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in
patients with advanced oesophageal squamous cell carcinoma refractory or
intolerant to previous chemotherapy (ATTRACTION-3). Lancet Oncol .
2019;20(11):1506-1517.
2. Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in
advanced esophageal squamous-cell carcinoma. N Engl J Med.2022;386(5):449-462.
3. Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint
blockade immunotherapy: radiosensitisation and potential mechanisms of
synergy. Lancet Oncol. 2015;16(13):e498-509.
4. Suzuki Y, Mimura K, Yoshimoto Y, et al. Immunogenic tumor cell death
induced by chemoradiotherapy in patients with esophageal squamous cell
carcinoma. Cancer Res. 2012;72(16):3967-3976.
5. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of
the abscopal effect in a patient with melanoma. N Engl J Med.2012;366(10):925-931.
6. Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of
radiotherapy on advanced melanoma patients who progressed after
ipilimumab immunotherapy. Oncoimmunology. 2014;3:e28780.
7. Du D, Song T, Dai H, Zhao J, Chen P, Wu S. Stereotactic body
radiation therapy and thymosin alpha-1-induced anti-tumor effects in
heavily pretreated, metastatic esophageal squamous cell carcinoma
patients. Oncoimmunology. 2018;7(8):e1450128.
8. Zhao X, Kang J, Zhao R. Abscopal effect of radiation on lymph node
metastasis in esophageal carcinoma. Oncol Lett.2018;16(3):3555-3560.
9. Chen DS, Mellman I. Oncology meets immunology. Immunity.2013;39(1):1-10.
10. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after
chemoradiotherapy in stage III non-small-cell lung cancer. N Engl
J Med. 2017;377(20):1919-1929.
11. Faivre-Finn C, Vicente D, Kurata T, et al. Four-year survival with
durvalumab after chemoradiotherapy in stage III NSCLC-an update from the
PACIFIC trial. J Thorac Oncol. 2021;16(5):860-867.
12. https://clinicaltrials.gov/
13. Sha CM, Lehrer EJ, Hwang C, et al. Toxicity in combination immune
checkpoint inhibitor and radiation therapy. Radiother Oncol.2020;151:141-148.
14. Smith EL, Mailankody S, Staehr M, et al. BCMA-targeted CAR T-cell
therapy plus radiotherapy for the treatment of refractory myeloma
reveals potential synergy. Cancer Immunol Res.2019;7(7):1047-1053.
15. Sridharan V, Margalit DN, Lynch SA, et al. Definitive chemoradiation
alters the immunologic landscape and immune checkpoints in head and neck
cancer. Br J Cancer . 2016;115(2):252-260.
16. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces
responses by inhibiting adaptive immune resistance. Nature.2014;515(7528):568-571.
17. Gros A, Robbins PF, Yao X, et al. PD-1 identifies the
patient-specific CD8⁺ tumor-reactive repertoire infiltrating human
tumors. J Clin Invest. 2014;124(5):2246-2259.
18. Zhang L, Kandadi H, Yang H, et al. Long-term sculpting of the B-cell
repertoire following cancer immunotherapy in patients treated with
sipuleucel-T. Cancer Immunol Res. 2020;8(12):1496-1507.
19. Brooks ED, Chang JY. Time to abandon single-site irradiation for
inducing abscopal effects. Nat Rev Clin Oncol.2019;16(2):123-135.